Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) signaling pathway mutations offer insights into targeted therapies for colorectal cancers.
• Analyzing PI3K/PTEN/AKT and RAS/RAF/MAPK pathways is crucial for understanding colorectal cancer progression.

Purpose of the Study:

• To identify mutations in the PI3K/PTEN/AKT and RAS/RAF/MAPK pathways in colorectal cancers.
• To investigate the association of these mutations with metastasis sites and recurrence patterns.

Main Methods:

• Retrospective analysis of 1,492 stage I-IV colorectal cancer specimens collected between 2000 and 2010.
• Utilized MALDI-TOF mass spectrometry to analyze 61 hotspot mutations in nucleic acids.

Main Results:

• RAS pathway mutations occurred in 47.3% of patients; PI3K pathway mutations in 14.3%; 9.2% had mutations in both.
• RAS and PI3K pathway mutations were associated with proximal and mucinous tumors, and microsatellite instability.
• RAS pathway mutations correlated with increased lung and peritoneal metastasis; NRAS mutations specifically linked to lung metastasis.

Conclusions:

• Somatic mutations in the RAS pathway of primary colorectal tumors can significantly influence metastasis patterns.
• These findings highlight the importance of RAS pathway mutations in predicting colorectal cancer spread and recurrence.